Fluvoxamina
Fluvoxamine
Fluvoxamine maleate
También conocido como: Luvox CR · Dumirox · Faverin · Fevarin · DU-23000 · desifluvoxamin · Dumyrox · Favoxil · Felixsan · Flox-ex · Floxyfral · Fluvohexal · Fluvoxadura · Fluvoxin · Maveral
Revisado por el equipo veterinario de VetSheetActualizado 5 abr 2026Referencia veterinaria basada en la evidencia
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Dosis por especie
🌎 NA — North America🌍 EU — Europe
Perros
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| For treatment of compulsive disorders | 0.5-2 mg/kg PO twice daily | PO | q12h | — | 🌎 NA |
| For treatment of behavioral diagnoses | 1-3 mg/kg PO once daily (q24h) | PO | q24h | allow 8 weeks for initial trial | 🌎 NA |
| For treatment of behavioral diagnoses | 1 mg/kg PO q12-24h | PO | q12-24h | Treat for 3-5 weeks minimum to assess effects; then treat until 'well' (minimum another 1-2 months). Continue for another 1-2 months minimum. | 🌎 NA |
- For treatment of behavioral diagnoses: Treatment should last for a minimum 4-6 months once initiating therapy. If weaning off, do so over 3-5 weeks (or longer).
Gatos
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| For treatment of compulsive disorders | 0.25-0.5 mg/kg PO once daily | PO | q24h | — | 🌎 NA |
| For treatment of behavioral diagnoses | 0.25-0.5 mg/kg PO q24h | PO | q24h | Treat for 3-5 weeks minimum to assess effects; then treat until 'well' (minimum another 1-2 months). Continue for another 1-2 months minimum. | 🌎 NA |
| For spraying | 0.25 mg/kg PO q12h | PO | q12h | — | 🌎 NA |
| For treatment of behavioral diagnoses | 0.5-1 mg/kg PO once daily (q24h) | PO | q24h | allow 8 weeks for initial trial | 🌎 NA |
- For treatment of behavioral diagnoses: Treatment should last for a minimum 4-6 months once initiating therapy. If weaning off, do so over 3-5 weeks (or longer).
- For spraying: Avoid use with benzodiazepines
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Resumen
La fluvoxamina es un antidepresivo inhibidor selectivo de la recaptación de serotonina (ISRS) utilizado en medicina veterinaria para tratar una variedad de trastornos del comportamiento en perros y gatos, incluyendo la agresividad y los comportamientos estereotipados u obsesivo-compulsivos.
Aunque no se prescribe con tanta frecuencia como la fluoxetina, sirve como una alternativa viable para el manejo conductual.
Perlas clínicas:
- Al igual que todos los ISRS, la fluvoxamina requiere un período de prueba prolongado (típicamente 6-8 semanas) para lograr la eficacia clínica completa debido al tiempo necesario para la regulación a la baja de los neurorreceptores.
- No debe suspenderse abruptamente; se recomienda una reducción gradual durante 3-5 semanas para evitar signos de abstinencia.
- La anorexia es un efecto secundario común, aunque generalmente transitorio, en perros que a veces puede manejarse alimentando a mano o aumentando la palatabilidad de los alimentos.
Mecanismo de acción
Fluvoxamine acts by highly selective inhibition of the serotonin transporter (SERT) in the central nervous system.
Mechanism: Blockade of presynaptic reuptake → increased concentration of serotonin (5-HT) in the synaptic cleft → prolonged receptor stimulation. Over time, this chronic elevation leads to the down-regulation and desensitization of post-synaptic 5-HT receptors, which correlates with the delayed onset of clinical behavioral improvement. It has minimal to no effect on dopamine or norepinephrine reuptake.
Seguridad y advertencias
Contraindicaciones
- Patients with known hypersensitivity to fluvoxamine or other SSRIs
- Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) such as selegiline or amitraz
- Concurrent use of cisapride
Efectos adversos
- Anorexia/decreased appetite (common)
- Lethargy or sedation
- Gastrointestinal upset (vomiting, diarrhea)
- Anxiety, irritability, or agitation
- Insomnia or hyperactivity
- Panting (dogs)
- Changes in elimination patterns (cats)
- Paradoxical aggressive behavior in previously non-aggressive dogs
Precauciones
Caution: Use with care in patients with severe cardiac, renal, or hepatic disease. Dosages may need to be reduced in patients with severe renal or hepatic impairment, or in geriatric patients.
- Pregnancy: FDA Category C. Animal studies in rats showed increased pup mortality at birth and decreased birth weights.
- Lactation: Fluvoxamine enters maternal milk, though it appears unlikely to be of significant clinical concern.
Interacciones farmacológicas
Fluvoxamine may paradoxically decrease the clinical efficacy of buspirone.
Fluvoxamine may increase plasma levels of cisapride, leading to toxicity. Concurrent use is contraindicated.
May decrease or reverse the effects of SSRIs (useful in treating serotonin syndrome).
Fluvoxamine may increase diazepam (and other benzodiazepine) levels.
Fluvoxamine may increase the effects of diltiazem; bradycardia has been reported in humans.
High risk for serotonin syndrome; contraindicated. A 5-week washout is required after stopping fluvoxamine, and a 2-week washout if stopping the MAOI first.
Fluvoxamine may increase plasma levels of methadone, leading to toxicity.
Increased plasma levels of phenytoin possible.
Fluvoxamine may increase these beta-blockers' plasma levels; atenolol may be safer.
Fluvoxamine may increase plasma levels of theophylline.
SSRIs can inhibit the metabolism of tramadol to active metabolites, decreasing efficacy and increasing toxicity risk (serotonin syndrome, seizures).
Fluvoxamine may increase TCA blood levels and increase the risk for serotonin syndrome.
Fluvoxamine may increase the risk for bleeding.
Monitorización
- Clinical efficacy (behavioral improvement)
- Adverse effects, particularly appetite and body weight
- Baseline liver function tests (consider re-testing as needed)
- ECG (consider baseline and re-test as needed)
Farmacocinética
Vida media
Absorción
In dogs, fluvoxamine appears to be completely absorbed. In humans, it is absorbed after oral administration with a bioavailability of around 50%. Food does not appear to affect absorption.
Distribución
In humans, it is widely distributed in the body and about 80% bound to plasma proteins.
Metabolismo
Extensively metabolized in the liver to non-active metabolites.
Eliminación
Eliminated primarily in the urine. In dogs, only about 10% of a dose is excreted unchanged in the urine.
Sobredosis
Limited data exists for animals. Any dosage over 10 mg/kg can reportedly cause tremors and lethargy.
Clinical Signs of Overdose: Vomiting, somnolence/coma, tremors, diarrhea, hypotension, heart rate/rhythm disturbances (bradycardia/tachycardia, ECG changes), and seizures. Fatalities have been reported in human overdoses.
Treatment:
- Standard protocols for GI decontamination (drug adsorption/removal) for potentially dangerous overdoses.
- Symptomatic and supportive therapy.
- Serotonin Syndrome Management: Cyproheptadine (1.1 mg/kg PO or rectally) may be used as an adjunctive treatment to negate serotonin effects.
- Seizure Control: Diazepam may be used to treat seizures or other severe neurologic signs.
Productos disponibles
Formulaciones
- Oral tablets
- Oral extended-release capsules
Etiquetado para humanos
- Fluvoxamine Oral Tablets: 25 mg, 50 mg, & 100 mg (Luvox®, generic)
- Fluvoxamine Oral Extended-release Capsules: 100 mg & 150 mg (Luvox CR®)
Estado regulador
Sin datos reguladores para: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Almacenamiento y estabilidad
Commercially available tablets should be stored in tight containers at room temperatures of 15-30°C (59-86°F) and protected from high humidity.
Información para el cliente
- La paciencia es clave: Este medicamento no funcionará de inmediato. Por lo general, requiere un compromiso de 6 a 8 semanas de uso continuo para observar una mejora significativa en el comportamiento.
- Entrenamiento conductual: La fluvoxamina es más efectiva cuando se combina con un programa profesional de modificación de conducta.
- Efectos secundarios: Esté atento a la disminución del apetito, letargo, vómitos o comportamiento anormal (como aumento de la ansiedad o agresividad). Si su mascota deja de comer por completo, comuníquese con su veterinario.
- Almacenamiento seguro: Mantenga este medicamento estrictamente fuera del alcance de niños y otras mascotas.
- No suspenda el tratamiento abruptamente: Si es necesario interrumpir el tratamiento, su veterinario le guiará sobre cómo reducir gradualmente la dosis para prevenir síntomas de abstinencia.
La referencia de medicamentos de VetSheet está destinada a profesionales veterinarios autorizados como ayuda para la toma de decisiones clínicas, no como sustituto del criterio profesional ni del prospecto actual del fabricante.